Methylcholanthrene-induced sarcomas develop independently from NOX2-derived ROS

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ligtenberg, Maarten A ^a   Çinar, Özcan ^a   Holmdahl, Rikard ^a   Mougiakakos, Dimitrios ^b   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CELL MEMBRANE PROTEIN; CISPLATIN; PROTEIN NCF1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; UNCLASSIFIED DRUG; CYBB PROTEIN, MOUSE; MEMBRANE PROTEIN; NEUTROPHIL CYTOSOLIC FACTOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; EFFECTOR CELL; GAMMA RADIATION; HETEROZYGOSITY; HOMOZYGOSITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MEMORY CELL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; OXIDATIVE STRESS; POINT MUTATION; PROTEIN FUNCTION; PROTEIN SUBUNIT; RADIOSENSITIVITY; REGULATORY T LYMPHOCYTE; SARCOMA; TUMOR GROWTH; ANIMAL; CD4 CD8 RATIO; CELL TRANSFORMATION; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOMODULATION; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ANIMALS; CD4-CD8 RATIO; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; METHYLCHOLANTHRENE; MICE; MICE, KNOCKOUT; MUTATION; NADPH OXIDASE; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SARCOMA; TUMOR BURDEN;

EID: 84950155373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129786     Document Type: Article

References (50)

1. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014; 6(2):114-8. PMID: 24489990
2. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjöberg J, Pisa P, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999 Oct; 48(7):353-62. PMID: 10501847
3. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Research. 1953 Dec; 13(12):835-7. PMID: 13116120
4. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun; 18(6):769-78. PMID: 13502695
5. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthreneinduced sarcomas in the primary autochthonous host. Cancer Research. 1960 Dec 1; 20:1561-72. PMID: 13756652
6. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. ScienceDirectNew insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. Elsevier Ltd; 2014 Apr 1; 27:16-25. doi: 10.1016/j.coi.2014.01.004 PMID: 24531241
7. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. P Natl Acad Sci Usa. 2008 Jan 15; 105(2):652-6. doi: 10.1073/pnas.0708594105 PMID: 18178624
8. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T Cells in Cancer. 2010 Jan 19;:1-74.
9. Mao Y, Poschke I, Kiessling R. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J Intern Med. 2014 Aug; 276(2):154-70. doi: 10.1111/joim.12229 PMID: 24597954
10. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Free Radical Biology & Medicine. Free Radic Biol Med. Elsevier Inc; 2010 Dec 1; 49(11):1603-16. doi: 10.1016/j.freeradbiomed.2010.09.006 PMID: 20840865
11. Mehrotra S, Mougiakakos D, Johansson CC, Voelkel-Johnson C, Kiessling R. Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res. 2009; 102:197-227. doi: 10.1016/S0065-230X(09)02006-5 PMID: 19595310
12. Nishigori C, Hattori Y, Toyokuni S. Role of reactive oxygen species in skin carcinogenesis. Antioxid Redox Signal. 2004 Jun; 6(3):561-70. PMID: 15130282
13. Pagano G, Aiello Talamanca A, Castello G, Cordero MD, d'Ischia M, Gadaleta MN, et al. Oxidative Stress and Mitochondrial Dysfunction across Broad-Ranging Pathologies: Toward Mitochondria-Targeted Clinical Strategies. Oxidative Medicine and Cellular Longevity. 2014; 2014(12):1-27.
14. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol. 2010 Jan; 38(1):96-109. doi: 10.1177/0192623309356453 PMID: 20019356
15. Milkovic L, Siems W, Siems R, Zarkovic N. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des. 2014; 20(42):6529-42. PMID: 25341930
16. Brandes RP, Weissmann N, Schröder K. Free Radical Biology and Medicine. Free Radic Biol Med. Elsevier; 2014 Nov 1; 76(C):208-26.
17. Rao. Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells. Int J Oncol. 2010 Oct 22; 37(6).
18. Mishra SK, Kang J- H, Lee CW, Oh SH, Ryu JS, Bae YS, et al. Midazolam induces cellular apoptosis in human cancer cells and inhibits tumor growth in xenograft mice. Mol Cells. 2013 Sep 2; 36(3):219-26. doi: 10.1007/s10059-013-0050-9 PMID: 24008365
19. Lu JP, Monardo L, Bryskin I, Hou ZF, Trachtenberg J, Wilson BC, et al. Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer and Prostatic Diseases. Nature Publishing Group; 2009 Jun 23; 13(1):39-46. doi: 10.1038/pcan.2009.24 PMID: 19546883
20. Maraldi T, Prata C, Vieceli Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D, et al. NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res. 2009 Jan; 43 (11):1111-21. doi: 10.1080/10715760903186132 PMID: 19707918
21. Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood. 2009 Apr 9; 113(15):3542-5. doi: 10.1182/blood-2008-09-181040 PMID: 19050306
22. Hultqvist M, Olofsson P, Holmberg J, Ba¨ckström BT, Tordsson J, Holmdahl R. Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene. P Natl Acad Sci Usa. 2004 Aug 24; 101(34):12646-51. PMID: 15310853
23. Sareila O, Jaakkola N, Olofsson P, Kelkka T, Holmdahl R. Identification of a region in p47phox/NCF1 crucial for phagocytic NADPH oxidase (NOX2) activation. J Leukoc Biol. 2013 Feb 28; 93(3):427-35. doi: 10.1189/jlb.1211588 PMID: 23271700
24. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009 May 1; 182(9):5693-701. doi: 10.4049/jimmunol.0900092 PMID: 19380816
25. Liu-Smith F, Poe C, Farmer PJ, Meyskens FL Jr. Amyloids, melanins and oxidative stress in melanomagenesis. Exp Dermatol. 2014 Nov 18; 24(3):171-4. doi: 10.1111/exd.12559 PMID: 25271672
26. Sareila O, Kelkka T, Pizzolla A, Hultqvist M, Holmdahl R. NOX2 Complex-derived ROS as Immune Regulators. Antioxid Redox Signal. 2011 Apr 11.
27. Rosenau W, Morton DL. Tumor-Specific Inhibition of Growth of Methylcholanthrene-Induced Sarcomas in Vivo and in Vitro by Sensitized Isologous Lymphoid Cells. J Natl Cancer Inst. 1966; 36(5):825-&.
28. Kono K, Petersson M, Ciupitu AM, Wen T, Klein G, Kiessling R. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines. Cancer Research. 1995 Dec 1; 55(23):5648-55. PMID: 7585649
29. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. Nature Publishing Group; 2014 Dec 12; 482(7385):400-4.
30. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60. PMID: 15032581
31. Ushmorov A, Hack V, Dröge W. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. Cancer Research. AACR; 1999; 59(14):3527-34. PMID: 10416620
32. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. Nature Publishing Group; 2015 Jan 26; 482(7385):405-9.
33. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002 Nov; 3(11):999-1005. PMID: 12407407
34. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, et al. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Research. 1999 Jun 15; 59(12):2950-6. PMID: 10383160
35. Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 2013 Aug 15; 122(7):1105-13. doi: 10.1182/blood-2012-08-449413 PMID: 23757729
36. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. Science Translational Medicine. 2014; 6(237). doi: 10. 1126/scitranslmed.3008639 PMID: 24848258
37. Kelkka T, Pizzolla A, Laurila JP, Friman T, Gustafsson R, Ka¨llberg E, et al. Mice lacking NCF1 exhibit reduced growth of implanted melanoma and carcinoma tumors. PLoS ONE. 2013; 8(12):e84148. doi: 10.1371/journal.pone.0084148 PMID: 24358335
38. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumorbearing mice. The Journal of Immunology. 2008 Oct 15; 181(8):5791-802. PMID: 18832739
39. Mailloux AW, Clark A-MA, Young MRI. NK depletion results in increased CCL22 secretion and Treg levels in Lewis Lung Carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. Int J Cancer. 2010 Mar 2; 127(11):2598-611. doi: 10.1002/ijc.25281 PMID: 20198623
40. Ngiow SF, Scheidt von B, Möller A, Smyth MJ, Teng MWL. The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. Oncoimmunology. 2014 Oct 28; 2(2):e23036. PMID: 23524369
41. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009 Mar 1; 9(3):162-74. doi: 10.1038/nri2506 PMID: 19197294
42. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. Journal of Experimental Medicine. 2007 May 29; 204(6):1463-74. PMID: 17548519
43. Alfred LJ, Wojdani A, Nieto M, Perez R, Yoshida G. A chemical carcinogen, 3-methylcholanthrene, alters T-cell function and induces T-suppressor cells in a mouse model system. Immunology. 1983 Oct; 50(2):207-13. PMID: 6225728
44. Indrová M, Bubeník J. Inhibition of cell-mediated cytotoxicity against tumor-associated antigens by suppressor lymph node cells from mice bearing methylcholanthrene-induced sarcomas. Neoplasma. 1979; 26(4):405-12. PMID: 160510
45. Tawara I, Take Y, Uenaka A, Noguchi Y, Nakayama E. Sequential involvement of two distinct CD4+ regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res. 2002 Aug; 93(8):911-6. PMID: 12716469
46. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004 Jan 15; 172(2):989-99. PMID: 14707072
47. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996 Jun; 26 (6):1308-13. PMID: 8647210
48. Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. Am Soc Hematology; 2014; 123(17):2663-72. doi: 10.1182/blood-2013-10-532200 PMID: 24553174
49. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 Apr 26; 410 (6832):1107-11. PMID: 11323675
50. Holmdahl R, Sareila O, Pizzolla A, Winter S, Hagert C, Jaakkola N, et al. Hydrogen Peroxide As an Immunological Transmitter Regulating Autoreactive T Cells. Antioxid Redox Signal. 2013 Apr 20; 18 (12):1463-74. doi: 10.1089/ars.2012.4734 PMID: 22900704